The Use of Perfusion MRI Using Ferumoxytol and Small Molecular Weight Gadolinium (Gd) Agents to Assess Response to Pembrolizumab in Brain Metastases and Systemic Lesions in NSCLC: A Comparison of Imaging Modalities to Address Brain Metastases, Pseudoprogression, and Systemic Lesion Tumor Flare (Neuro-Check Pilot)
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2018
At a glance
- Drugs Ferumoxytol (Primary) ; Pembrolizumab
- Indications Brain metastases; Non-small cell lung cancer
- Focus Diagnostic use
- 31 Aug 2018 Biomarkers information updated
- 15 Nov 2017 Status changed from not yet recruiting to recruiting.
- 06 Nov 2017 Planned initiation date changed from 31 Oct 2017 to 6 Nov 2017.